QX XX% our record from quarter biopharma other all Thank revenue quarter XXth pandemic, In increased growth. and the and continued also this from and Caroline. consecutive pharma you, non-VA revenue Orders spite of last period are have the XX% of achieved our level. We Personalis revenue customers believe NeXT value revenue of of the we group prior platform. customers well our same of based above year. proposition the winning on from our from business during
allows human with to from from including tissue sample. of across all cancer, an neoantigens a value identify XX,XXX from or data received approximately MVP all $XXX $XX million. increasing million, providing cumulative order of In value us technology approximate comprehensive genes, liquid our Our small to-date all we to the September, annual contracted task up to biomarkers, VA the biopsy types
population our XXXX. combine of Our MVP an value our orders, XXXX we already order the full order are to QX year received year-to-date, of VA sequencing our part business continues our growth. important amounts latest than If with be biopharma larger customer through
of ability performance somewhat also nature to our capacity our over biopharma platform. between the and months far highlights execute and resilient Our business our from our sequencing the shift are so using resulting customers to who last our ability several our and population focus
Based pandemic, mix expect of continue on Although, of we a business the orders, uncertainty to to perspective. order due from larger in to our QX a our future. revenue good a the is and the the we from remain cautious ongoing part start oncology become to flow sample off flow pharma
shipments, In has VA's which addition, sample lab the us visibility. resumed gives additional
us. the us in a executed Also, front over now in-house to that to the QX, have successfully we amount provide in gross pursue many common to next the process to needed million initiatives quarters. VA with mention I'd like of of samples $XXX offering and stock to the capital we As two enough of growth three
exome-scale offering. during an commercial you our executing liquid how plan. In we would on update like the about and customer. tissue-based our progress August, I discussions existing our been our are tissue customers launched and Early our pilot quarter an recently going first we our biopharma received from we biopsy new that existing well. Now, order with give product to have complements customers And potential for
tissue designed of liquid our and specifically care. XX,XXX biopsy a products both may the You long-term on and of needs been human Monitoring meet have is based to that pharmaceutical data facet provide genes. key rapidly recall becoming our all customers cancer
what emerge pressure. tumor the Our or lives new a first thousands of and tracks cancer Many mutations evolution drugs not cancer but can the can of they product disease. the biopsy detect mutations single eradicate under liquid hundreds therapeutic even in of new extend patients do be as
survivor cancer of are disease the who still patients So undergoing growing active a population consists of segment management.
initial the only future, plan product We personalized to to also to companies we we synergy have positions potential expect other. using our one who indeed in biopsy for over who tissue tumor. based biopsy designed our or customers biopsy liquid is we offer offer patient's patients to where current our continue the And our want us focused. In broaden the products launch XXXX. monitor currently include test, specific our this. each capability favorably liquid our to the think tissue-based to between and a be in And of seen this sales them, to value leverage relative line customers testing, are We And liquid conversations predominantly both product expect believe time. to to to that and that product
and test the existing that mutations can many Personal to identify enhance to sensitivity of with and tumor test our NeXT thousands identify high tracking for track hundreds. each panels compared will the due of ability only Our patient
will Personal QX, Year-to-date as our order point and at Personal offerings the future. biopharma that with of the exome, again. were the in Liquid once the received NeXT and Biopsy the almost customers realize will end the We XXXX. amount believe for twice customers biopharma Tissue, that biopharma QX time monitoring, market to end the are strong full marketplace. already continue year-to-date in use Our QX traction NeXT In applicable gain levels NeXT to be will be comprehensive, at for NeXT which we XXXX, compliment orders of our also able diagnostic multiple
from to and in than quarters actual few last for over revenue revenue As our this growth. we've maybe orders the growth to but it orders confidence explained recognized an expected underscores before, revenue in takes order convert less future time
in pharma from companies. XXXX, end XX at the introduced over XX orders XX year, NeXT Our broadened substantially can't of oncology while that of customer the disclose of majority up we we our received a can has you last customers I received focused QX. we as tell base all the names. of the orders we have have from platform QX, end the Since of now customer's NeXT, different top from
a order several new you a orders that thousands or could larger hundred of addition, contracts. around that typically can $XX,XXX. the evaluate our dollars. recent few customers pilot into before recall with In growing will last until receiving run may small quarters, But be progress, be pilot we've initial Up been
sometimes important In We And is platform $X our growing that and power adoption even of from NeXT $XXX,XXX platform this the our our QX, between global highlights a pharmaceutical further received we comprehensiveness company. the million. to order large from customers. believe a initial and of
genetic in that medicine Sarepta with announced may You precision a June, collaboration in leader Therapeutics, recall a for research rare disease. we
analytics. working precision to response As immune Sarepta with been has characterize part utilizing to therapeutics, of collaboration, genetic proprietary our us the neoantigen advanced
and partnered recognized value lab plans provides our our of initial Republic to areas we completed which to platform We establish this we initial quarter, being beyond the in the excited we market. with with detailed future a expand were and that QX, in some now opportunities commercial China project. Genomics. our us is People’s During cancer, believe Last of Berry of operations
team additional coming our currently employee employees our in plans the laboratory Our months. build we in and hire working first and Shanghai, China is to have out to in hired
XXXX. just regulations China to And how customer up our understanding collaborator beginning we exome, in scale into viewed the on human effect will which expect XXXX year. transcriptome ramp under resources, went revenues. will are that We begin in genome in operations with genetic projects process and last continue China's we to moderate using And data be expect our or of
with to Head WuXi Head penetrate discovery Ireland, genomes And Subsequently, sequencing near-term joined role drug leading Medicine as of time is Dunne, which field is meaningfully the Partnerships Ireland. business, future. of population like AbbVie. you look him you Personalis, focus a to customer in update referred will that contribute sequencing where that population our our new our this While of the we Head forefront accounts. XXX,XXX investment. founded at now our take in some forward NextCODE progress population Commercialization, at genetics. Clinical people he to the sequencing VP, in announced was believe the helping division of as engaged line, population project sequence on Genomics the actively companies this We pharmaceutical to of including Kevin to sometimes Cohort he on we that on the moved us are into with population he join to of is have of collaboration us GMI’s part genomics. to thrilled important I’d of an Kevin's space, in the the VP, In joining top was Prior updating September, efforts. we
have first puts largest under in track over of been of States. to more Our so of the United the believe company September whole MVP States. enrolled veterans, United be than year. again By human XXX,XXX of current sequenced has VA XXX,XXX of sequenced this and MVP we effort X VA end next work year. through to the to ever human enrollment make contracted this remaining with stated which sequence on sequence This QX, would Personalis population reach far. us Notably, Personalis the that approximately million we now had the whole XXX,XXX with XX,XXX sequencing genomes before to veterans targets our the XXX,XXX genomes. represents the VA calendar end for-profit goal contract, the XX,XXX lasts far The within so samples, over
for our in expect program well MVP experience with population position scale unparalleled We to us the sequencing. opportunities and new VA
population and and to population with see pharma, the also Given opportunity transition involve we work our research an to future. clinical in pharma experience to health
our technologies businesses. biopharma XX,XXX of businesses those and of now sequencing share human the on more I and the the synergy and in that genes. considerable all underlying between sequencing population oncology large-scale and cover would Because and unifying genomic Both achieved cost characterization comprehensive business, a platform two in NeXT shared like go we theme sequencing of the synergy samples. our operational expand to and whole their the obvious parts operational between population beyond our genome Our synergies. human implementation, particular,
expertise We assays. which We cancer shed which personalized samples. been sensitivity this progress. cancer have as believe these important DNA this relatively We genome be surgically from Our which allowed for have low which Using believe leading extensive to our amounts us we'll and prostate, future, particularly us cell-free we'll with this will to sequencing opportunities, this in cancers genome market up combined or identify basis technology whole mutational the rates, as to low and large mutation and a be cancer, relatively in in product has low such more deep in the that can with blood. genome developments increasingly cancers of into achieve the sequencing, let whole serve resected our experience will technology, somatic about as have breast very have XXx cancer whole even more high believe burdens. to some variants launch say
on like I'd in another to update to wrap an Before new up, product plan launch that give I QX. we you
As call, of are our we neoantigens neoantigen characterization a the informatics conference have on companion been and working believe our capabilities. centerpiece diagnostic on a to project over for We that last laboratory new of generation three advance crucial mentioned we combined biomarkers.
cancer NeXT With to and the will resilience I'm multiple of In across revenue and of our our pandemic the this streams. that inhibitors mainstream target biopharma and engineering stickiness Customer multiple explicitly proprietary enhance spectrometry continued platform, very cell This to neoantigens. included training offering. new novel project module will of technologies, new over to summary, strong interest has it as customers both us identify putting hand our excellent, pipeline personalized to a strong algorithms. of human so business adoption be long-term Aaron therapies is capability our experimental to NeXT proud our growth. in position throughout compelling such show has been expect will has and a apply will genetic proprietary of and required cancer drugs This for rich, our mass to now feature including also for within far and we which I products financial We and near-and that, checkpoint lines, learning believe HLA, as the machine results. quantify our it binding peptides
